A partnership with the Center for Molecular Medicine (CMM) of Grand Rapids Michigan has been specially designed to propel the center's clinical research while providing Xceed Molecular with additional real-world clinical laboratory experience and access to critical research results. Under the leadership of Daniel H. Farkas, PhD, HCLD, the research team at CMM is undertaking a number of projects including the investigation and development of cancer diagnostics and improved sample preparation methods – with the support of Xceed's gene expression services.

Dr. Farkas said, "We are very pleased to be supporting Xceed's efforts to bring its clinical laboratory-friendly Ziplex System to the marketplace. The intersection of patient care and business represented by our international collaboration is central to the mission of the Center for Molecular Medicine. As a CLIA-certified, CAP accredited laboratory, the CMM will provide Xceed the opportunity to bring new array-based tests to the clinical community. The ease of use and initial data generated by the Ziplex System have been impressive. As translational medicine moves from the research laboratory to the clinic, technology that is affordable, reliable, and automated will be critical. We believe the Ziplex System is uniquely positioned to fulfill this need."